Sivia Capital Partners LLC Buys Shares of 3,674 Boston Scientific Co. (NYSE:BSX)

Sivia Capital Partners LLC acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,674 shares of the medical equipment provider’s stock, valued at approximately $212,000.

Other institutional investors also recently modified their holdings of the company. Bruce G. Allen Investments LLC acquired a new stake in Boston Scientific in the 4th quarter valued at $28,000. Sachetta LLC acquired a new stake in Boston Scientific in the 4th quarter valued at $32,000. Frazier Financial Advisors LLC acquired a new stake in Boston Scientific in the 4th quarter valued at $32,000. Jones Financial Companies Lllp boosted its stake in Boston Scientific by 53.0% in the 4th quarter. Jones Financial Companies Lllp now owns 557 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 193 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its stake in Boston Scientific by 58.0% in the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 215 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.7 %

NYSE:BSX opened at $76.19 on Tuesday. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $77.64. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. The stock has a market cap of $111.78 billion, a price-to-earnings ratio of 64.03, a PEG ratio of 2.64 and a beta of 0.81. The stock has a 50-day moving average price of $73.24 and a two-hundred day moving average price of $66.30.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.05. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. The firm had revenue of $3.86 billion during the quarter, compared to analysts’ expectations of $3.68 billion. As a group, equities analysts expect that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently commented on BSX shares. Needham & Company LLC boosted their price target on Boston Scientific from $71.00 to $82.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday. TD Cowen lifted their price objective on Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research report on Thursday, March 7th. Evercore ISI lifted their price objective on Boston Scientific from $72.00 to $78.00 and gave the company an “outperform” rating in a research report on Thursday, April 25th. Finally, Mizuho lifted their price objective on Boston Scientific from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, May 15th. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $76.70.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 14,011 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $75.34, for a total transaction of $1,055,588.74. Following the completion of the transaction, the executive vice president now directly owns 20,197 shares in the company, valued at $1,521,641.98. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP Arthur C. Butcher sold 14,011 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $75.34, for a total transaction of $1,055,588.74. Following the completion of the transaction, the executive vice president now directly owns 20,197 shares in the company, valued at $1,521,641.98. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $75.33, for a total value of $526,029.39. Following the transaction, the executive vice president now owns 45,628 shares of the company’s stock, valued at $3,437,157.24. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,627 shares of company stock valued at $5,937,353. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.